Liraglutide by Novo Nordisk
Non-diabetic hyperglycaemia gets a new drug Liraglutide (Saxenda) which is indicated for adults who are also facing high risk cardiovascular disease.
Based on a recommendation by National Institute for Health and Care Excellence (NICE) Liraglutide can now be administered to adults who undergoing treatment for obesity and non-diabetic hyperglycaemia. It is believed that a combination of Liraglutide, a reduced-calorie diet and increased physical activity will efficiently manage the condition.
Liraglutide manufactured by Novo Nordisk can be offered to adults with body mass index (BMI) of at least 35 kg/m2 and are at high risk of cardiovascular disease i.e. high blood pressure or high cholesterol levels.
Presentation of Liraglutide is pre-filled injection pens, guidance for use provided by NICE includes discontinuation of drug after 12 weeks of administration without weight loss up to 5 percent. The drug is to be prescribed by a specialist in multidisciplinary tier 3 weight management service.
Concerns over cost-effectiveness estimates have been a major limitation for low recommendation of Liraglutide. Novo Nordisk has moved to accept a confidential discount with National Health Service (NHS) England and NHS Improvement to mitigate the high cost uncertainty and potential which NICE considered was more than a cost-effective use of National Health Service (NHS) resources.
Clinical evidence demonstrated that Liraglutide induced weight loss in obesity when combined with a healthy lifestyle and was suggested to delay the development of type 2 diabetes and cardiovascular disease which is the main benefit of Liraglutide therapy.
Until now, the need for more treatment options for obese adults experiencing non-diabetic hyperglycaemia who are at high risk of diabetes type 2 and cardiovascular diseases was essential. Liraglutide is thus a significant contributor.